Literature DB >> 10904013

Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension.

A Ergul1.   

Abstract

The prevalence of essential hypertension in blacks is much higher than that in whites. In addition, the pathogenesis of hypertension appears to be different in black patients. For example, black patients present with a salt-sensitive hypertension characterized by low renin levels. Racial differences in renal physiology and socioeconomic factors have been suggested as possible causes of this difference, but reasons for this difference remain unclear. Endothelial cells are important in the regulation of vascular tonus and homeostasis, in part through the secretion of vasoactive substances. One of these factors, endothelin-1 (ET-1), is a 21 amino acid residue peptide with potent vasopressor actions. In addition to its contractile effects, it has been shown to stimulate mitogenesis in a number of cell types. Moreover, ET-1 displays modulatory effects on the endocrine system, including stimulation of angiotensin II and aldosterone production and inhibition of antidiuretic hormone in the kidney. Recent data from several laboratories indicate that ET-1 is overexpressed in the vasculature in several salt-sensitive models of experimental hypertension. Moreover, circulating plasma ET-1 levels are significantly increased in black hypertensives compared with white hypertensives. Thus, the ET system might be particularly important in the development or maintenance of hypertension in this population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904013     DOI: 10.1161/01.hyp.36.1.62

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  Molecular adaptations in vasoactive systems during acute stroke in salt-induced hypertension.

Authors:  Nicole M Ventura; Nichole T Peterson; M Yat Tse; R David Andrew; Stephen C Pang; Albert Y Jin
Journal:  Mol Cell Biochem       Date:  2014-11-13       Impact factor: 3.396

Review 2.  Long-term blood pressure control: is there a set-point in the brain?

Authors:  Yasuhiro Nishida; Megumi Tandai-Hiruma; Takehito Kemuriyama; Kohsuke Hagisawa
Journal:  J Physiol Sci       Date:  2012-05       Impact factor: 2.781

3.  Population strategies to treat hypertension.

Authors:  Daniel T Lackland
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

Review 4.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

5.  Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients.

Authors:  Seo Rin Kim; Alfonso Eirin; Sandra M S Herrmann; Ahmed Saad; Luis A Juncos; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

Review 6.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

7.  Three-year change in endothelin-1 and markers of vascular remodelling in a bi-ethnic South African cohort: the SABPA study.

Authors:  C S du Plooy; C M C Mels; H W Huisman; R Kruger
Journal:  J Hum Hypertens       Date:  2017-07-20       Impact factor: 3.012

8.  High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.

Authors:  I Brochu; M Houde; L Desbiens; E Simard; F Gobeil; W Semaan; G Bkaily; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 9.  Endothelin antagonists in hypertension and kidney disease.

Authors:  Kevin E C Meyers; Christine Sethna
Journal:  Pediatr Nephrol       Date:  2012-10-16       Impact factor: 3.714

Review 10.  Racial disparity in infant and maternal mortality: confluence of infection, and microvascular dysfunction.

Authors:  Kevin Fiscella
Journal:  Matern Child Health J       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.